Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08BZZ
|
|||
| Drug Name |
Omburtamab I-131
|
|||
| Indication | Neuroblastoma [ICD-11: 2D11.2; ICD-9: 194] | Phase 2/3 | [1] | |
| Small round cell desmoplastic tumour [ICD-11: 2A20.5; ICD-10: C49; ICD-9: 171] | Phase 1/2 | [2] | ||
| Company |
Y-mAbs Therapeutics New York, NY
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B7 homolog 3 (CD276) | Target Info | Inhibitor | [2], [3] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03275402) 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.